This Program Project focuses on elucidating the role and actions of novel specialized pro-resolving mediators (SPM) in acute inflammation and tissue injury. In service to this Program Project to achieve its mission and goals, this Core, Lipid Mediator-SPM Lipidomics, will provide centralized, standardized and coordinated lipid mediator (LM) lipidomic profiling procedures for Projects 1-3. This Core B will execute newly established methods for SPM identification, lipidomics and LM pathway profiling metabolomics as a central service that will be required routinely by Projects 1-3. Core B will also develop, validate and implement new lipidomic approaches when needed. By providing a centralized location for the identification of LM and SPM, their profiling and pathway metabolomics as standardized services, this core eliminates costly duplication of instruments and personnel within each of the projects. LM and SPM validation will be carried out by Core B. This core will characterize the physical properties of synthetic compounds prepared by total organic synthesis in Core C, and shall match these using biophysical criteria for validation to biologically produced SPM and SPM-sulfido-conjugates (SPM-SC). These will include resolvins, protectins and maresins, as well as novel bioactive structures recently identified and biosynthetic pathway isomers, before distributing bioactive synthetic SPM to each project for assessing their functional roles. Prioritization of the services and selection of the specific procedures will be determined via individual meetings with project and core investigators at bimonthly Program Project group meetings to achieve optimal use of resources and experience of this Core in a cost-effective and timely fashion for the investigators within this Program Project.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
5P01GM095467-07
Application #
9250779
Study Section
Special Emphasis Panel (ZGM1)
Project Start
Project End
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
7
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Winkler, Jeremy W; Libreros, Stephania; De La Rosa, Xavier et al. (2018) Structural insights into Resolvin D4 actions and further metabolites via a new total organic synthesis and validation. J Leukoc Biol :
Wu, Bian; Werlin, Evan C; Chen, Mian et al. (2018) Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rabbit vein graft model. J Vasc Surg 68:188S-200S.e4
Motwani, Madhur P; Bennett, Frances; Norris, Paul C et al. (2018) Potent Anti-Inflammatory and Pro-Resolving Effects of Anabasum in a Human Model of Self-Resolving Acute Inflammation. Clin Pharmacol Ther 104:675-686
Norris, Paul C; Arnardottir, Hildur; Sanger, Julia M et al. (2018) Resolvin D3 multi-level proresolving actions are host protective during infection. Prostaglandins Leukot Essent Fatty Acids 138:81-89
Chiang, Nan; Riley, Ian R; Dalli, Jesmond et al. (2018) New maresin conjugates in tissue regeneration pathway counters leukotriene D4-stimulated vascular responses. FASEB J 32:4043-4052
Krishnamoorthy, Nandini; Abdulnour, Raja-Elie E; Walker, Katherine H et al. (2018) Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases. Physiol Rev 98:1335-1370
Chen, Gang; Zhang, Yu-Qiu; Qadri, Yawar J et al. (2018) Microglia in Pain: Detrimental and Protective Roles in Pathogenesis and Resolution of Pain. Neuron 100:1292-1311
Tungen, J E; Aursnes, M; Ramon, S et al. (2018) Synthesis of protectin D1 analogs: novel pro-resolution and radiotracer agents. Org Biomol Chem 16:6818-6823
Sulciner, Megan L; Serhan, Charles N; Gilligan, Molly M et al. (2018) Resolvins suppress tumor growth and enhance cancer therapy. J Exp Med 215:115-140
Loynes, Catherine A; Lee, Jou A; Robertson, Anne L et al. (2018) PGE2 production at sites of tissue injury promotes an anti-inflammatory neutrophil phenotype and determines the outcome of inflammation resolution in vivo. Sci Adv 4:eaar8320

Showing the most recent 10 out of 165 publications